ERBB2 and breast cancer: Based on this data, in 2020, the FDA and EMA first approved the ready-to-use fixed-dose combination of PH for subcutaneous (SC) injection (pertuzumab, trastuzumab, and hyaluronidase-zzxf; PH FDC SC) to treat adult patients with HER2-positive BC that has spread to other parts of the body, and for treatment of adult patients with early HER2-positive BC (EMA, 2020; FDA, 2020).